search
Back to results

Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma (AA007)

Primary Purpose

Allergic Asthma

Status
Completed
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Omalizumab
placebo
Sponsored by
Shanghai Zhangjiang Biotechnology Limited Company
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Allergic Asthma focused on measuring Omalizumab, IgE, Asthma

Eligibility Criteria

15 Years - 65 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female aged 15~65 years
  • Written informed consent provided
  • Total serum IgE >=60IU/ml
  • Duration of allergic asthma >= 1 year according to GINA(2008)
  • Poor response to moderate to high dose inhaled corticosteroid (400ug/day~800ug/day) >= 4 weeks
  • Agreed to be not pregnant, contraception during study and later 6 months.

Exclusion Criteria:

Patients who met the below criteria were excluded:

  • Be regular smokers(>10 cigarettes per day and for at least 2 years)
  • Patients who are currently pregnant or nursing or intend to become pregnant over the course of the study or later 6 months
  • COPD, according to the guideline of Chinese society of respiratory diseases
  • An active lung disease other than allergic asthma
  • Patients with significant underlying medical conditions
  • Allergic to immunoglobin or any formulation ingredient of the product
  • Patients with diabetes or uncontrolled hypertension(Systolic blood pressure>160mmHg or Diastolic blood pressure>95mmHg)
  • HIV positivity or cancer patient
  • Prior exposure to Xolair

Sites / Locations

  • China-Japan Friendship Hospital
  • Beijing Chaoyang Hospital
  • Peking Union Medical College Hospital
  • Peking University People's Hospital
  • The Second Hospital of Jilin University
  • West China Hospital, Sichuan University
  • Chongqing Xinqiao Hospital
  • Chinese PLA Fuzhou General Hospital of Nanjing Military Command
  • South Hospital of South Medical University
  • Sir Run Run Shaw Hospital of Zhejiang University
  • The First Affiliated Hospital of Zhejiang University
  • The Second Affiliated Hospital of Zhejiang University
  • Chinese PLA Jinan Military General Hospital
  • Shandong Provincial Hospital
  • Jiangsu Province Hospital
  • Zhongda Hospital, Southeast University
  • The First Affiliated Hospital of Guangxi Medical University
  • Qingdao Municipal Hospital
  • Shanghai Changzheng Hospital
  • Shanghai First People's Hospital
  • Zhongshan Hospital, Fudan University
  • Chinese PLA Shenyang Military Command General Hospital
  • The First hospital of China Medical University
  • The Second Hospital of Hebei Medical University
  • The Second Hospital of Tianjin Medica University
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and technology
  • Xi'an Xijing Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Omalizumab

placebo

Arm Description

During the 4~6-week Run-in phase, the dosage of budesonide inhaled powder(BUD) was prescribed and optimized to maintain asthma control according to Global Initiative for Asthma(GINA, 2008) guidelines. During the following treatment phase, patients continued to receive optimized BUD and Omalizumab for 28 weeks, administered by subcutaneous injection every 2 weeks or 4 weeks. The dosage of Omalizumab received was based on body weight and serum IgE.

During the 4~6-week Run-in phase, the dosage of budesonide inhaled powder(BUD) was prescribed and optimized to maintain asthma control according to Global Initiative for Asthma(GINA, 2008) guidelines. During the treatment phase, patients continued to receive placebo and optimized BUD for 28 weeks, administered by subcutaneous injection every 2 weeks or 4 weeks.

Outcomes

Primary Outcome Measures

The proportion of patients with asthma exacerbation

Secondary Outcome Measures

Pulmonary function measured by FEV1 and FEV1/FVC
Asthma symptoms evaluated by patients by using the Questionaire, Asthma Quality of Life Questionaire

Full Information

First Posted
October 23, 2013
Last Updated
December 20, 2015
Sponsor
Shanghai Zhangjiang Biotechnology Limited Company
search

1. Study Identification

Unique Protocol Identification Number
NCT01976208
Brief Title
Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma
Acronym
AA007
Official Title
A Multicenter, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Recombinant Humanized Anti-IgE Monoclonal Antibody Injection(Omalizumab) in Patients With Allergic Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
December 2015
Overall Recruitment Status
Completed
Study Start Date
December 2010 (undefined)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
December 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Shanghai Zhangjiang Biotechnology Limited Company

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary purpose is to evaluate the safety and efficacy of recombinant humanized anti-IgE monoclonal antibody injection in patients with allergic asthma.
Detailed Description
Omalizumab will be given as add-on treatment to budesonide inhaled powder in patients with moderate or severe allergic asthma(IgE>=60IU/ml), who demonstrate inadequate asthma symptom control. Response to Omalizumab will be assessed by the overall improvement in control of asthma. Omalizumab is a recombinant humanized monoclonal antibody that selectively binds to human immunoglobulin E(IgE). The antibody has a molecular weight of approximately 150 kilodaltons and produced by Chinese Hamster Ovary cell. Omalizumab inhibits the binding of IgE to the high-affinity IgE receptor on the surface of mast cells and basophils. Reduction in surface-bound IgE on cells limits the degree of release of mediators of the allergic response.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Allergic Asthma
Keywords
Omalizumab, IgE, Asthma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
630 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Omalizumab
Arm Type
Experimental
Arm Description
During the 4~6-week Run-in phase, the dosage of budesonide inhaled powder(BUD) was prescribed and optimized to maintain asthma control according to Global Initiative for Asthma(GINA, 2008) guidelines. During the following treatment phase, patients continued to receive optimized BUD and Omalizumab for 28 weeks, administered by subcutaneous injection every 2 weeks or 4 weeks. The dosage of Omalizumab received was based on body weight and serum IgE.
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
During the 4~6-week Run-in phase, the dosage of budesonide inhaled powder(BUD) was prescribed and optimized to maintain asthma control according to Global Initiative for Asthma(GINA, 2008) guidelines. During the treatment phase, patients continued to receive placebo and optimized BUD for 28 weeks, administered by subcutaneous injection every 2 weeks or 4 weeks.
Intervention Type
Drug
Intervention Name(s)
Omalizumab
Other Intervention Name(s)
other name: Aomaishu, Recombinant Humanized Anti-IgE Monoclonal Antibody
Intervention Description
The recommended dose is 0.016mg/kg/IgE(IU/ml) every 4 weeks. It is administered by subcutaneous injection.If the total dose per 4 weeks is 150~300mg, the dosing interval will be every 4 weeks; if the total dose per 4 weeks is 450mg~750mg,then dosing interval is every 2 weeks.
Intervention Type
Drug
Intervention Name(s)
placebo
Primary Outcome Measure Information:
Title
The proportion of patients with asthma exacerbation
Time Frame
32 weeks
Secondary Outcome Measure Information:
Title
Pulmonary function measured by FEV1 and FEV1/FVC
Time Frame
32 weeks
Title
Asthma symptoms evaluated by patients by using the Questionaire, Asthma Quality of Life Questionaire
Time Frame
32 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female aged 15~65 years Written informed consent provided Total serum IgE >=60IU/ml Duration of allergic asthma >= 1 year according to GINA(2008) Poor response to moderate to high dose inhaled corticosteroid (400ug/day~800ug/day) >= 4 weeks Agreed to be not pregnant, contraception during study and later 6 months. Exclusion Criteria: Patients who met the below criteria were excluded: Be regular smokers(>10 cigarettes per day and for at least 2 years) Patients who are currently pregnant or nursing or intend to become pregnant over the course of the study or later 6 months COPD, according to the guideline of Chinese society of respiratory diseases An active lung disease other than allergic asthma Patients with significant underlying medical conditions Allergic to immunoglobin or any formulation ingredient of the product Patients with diabetes or uncontrolled hypertension(Systolic blood pressure>160mmHg or Diastolic blood pressure>95mmHg) HIV positivity or cancer patient Prior exposure to Xolair
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nanshan Zhong, M.D.
Organizational Affiliation
The First Affiliated Hospital of Guangzhou Medical University
Official's Role
Study Chair
Facility Information:
Facility Name
China-Japan Friendship Hospital
City
Beijing
State/Province
Beijing
Country
China
Facility Name
Beijing Chaoyang Hospital
City
Beijing
Country
China
Facility Name
Peking Union Medical College Hospital
City
Beijing
Country
China
Facility Name
Peking University People's Hospital
City
Beijing
Country
China
Facility Name
The Second Hospital of Jilin University
City
Changchun
Country
China
Facility Name
West China Hospital, Sichuan University
City
Chengdu
Country
China
Facility Name
Chongqing Xinqiao Hospital
City
Chongqing
Country
China
Facility Name
Chinese PLA Fuzhou General Hospital of Nanjing Military Command
City
Fuzhou
Country
China
Facility Name
South Hospital of South Medical University
City
Guangzhou
Country
China
Facility Name
Sir Run Run Shaw Hospital of Zhejiang University
City
Hangzhou
Country
China
Facility Name
The First Affiliated Hospital of Zhejiang University
City
Hangzhou
Country
China
Facility Name
The Second Affiliated Hospital of Zhejiang University
City
Hangzhou
Country
China
Facility Name
Chinese PLA Jinan Military General Hospital
City
Jinan
Country
China
Facility Name
Shandong Provincial Hospital
City
Jinan
Country
China
Facility Name
Jiangsu Province Hospital
City
Nanjing
Country
China
Facility Name
Zhongda Hospital, Southeast University
City
Nanjing
Country
China
Facility Name
The First Affiliated Hospital of Guangxi Medical University
City
Nanning
Country
China
Facility Name
Qingdao Municipal Hospital
City
Qingdao
Country
China
Facility Name
Shanghai Changzheng Hospital
City
Shanghai
Country
China
Facility Name
Shanghai First People's Hospital
City
Shanghai
Country
China
Facility Name
Zhongshan Hospital, Fudan University
City
Shanghai
Country
China
Facility Name
Chinese PLA Shenyang Military Command General Hospital
City
Shenyang
Country
China
Facility Name
The First hospital of China Medical University
City
Shenyang
Country
China
Facility Name
The Second Hospital of Hebei Medical University
City
Shijiazhuang
Country
China
Facility Name
The Second Hospital of Tianjin Medica University
City
Tianjin
Country
China
Facility Name
Tongji Hospital, Tongji Medical College, Huazhong University of Science and technology
City
Wuhan
Country
China
Facility Name
Xi'an Xijing Hospital
City
Xi'an
Country
China

12. IPD Sharing Statement

Learn more about this trial

Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma

We'll reach out to this number within 24 hrs